Literature DB >> 12893110

Depression in Alzheimer's disease: heterogeneity and related issues.

Hochang B Lee1, Constantine G Lyketsos.   

Abstract

Several studies have demonstrated that the great majority of Alzheimer's disease (AD) patients suffer "noncognitive" neuropsychiatric symptoms. Depression is one of the most frequent neuropsychiatric comorbidities of AD. Affecting up to 50% of AD patients, depression in AD is associated with serious negative consequences for patients and their caregivers. Yet available studies on the natural course, etiology, and treatment of depression in AD have been few and equivocal. Heterogeneity in research methodology and etiology of depression in AD might have contributed to inconsistent findings across studies. Recently, the National Institute of Mental Health (NIMH) convened the Depression of Alzheimer's Disease Workgroup, which proposed provisional diagnostic criteria for depression of Alzheimer's Disease (NIMH-dAD). These criteria may provide a framework for future studies to clarify the unresolved issues in nosology, etiology, and treatment of depression in AD. A longitudinal cohort study of depression in incident AD cases may provide further syndrome refinement that would facilitate investigation of the etiology and treatment of depression in AD.

Entities:  

Mesh:

Year:  2003        PMID: 12893110     DOI: 10.1016/s0006-3223(03)00543-2

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  38 in total

1.  Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS-2)?

Authors:  Lea T Drye; Barbara K Martin; Constantine E Frangakis; Curtis L Meinert; Jacobo E Mintzer; Cynthia A Munro; Anton P Porsteinsson; Peter V Rabins; Paul B Rosenberg; Lon S Schneider; Daniel Weintraub; Constantine G Lyketsos
Journal:  Int J Geriatr Psychiatry       Date:  2011-06       Impact factor: 3.485

2.  Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in Caenorhabditis elegans.

Authors:  Roongpetch Keowkase; Marwa Aboukhatwa; Yuan Luo
Journal:  Neuropharmacology       Date:  2010-04-24       Impact factor: 5.250

3.  Rural-urban differences in preventable hospitalizations among community-dwelling veterans with dementia.

Authors:  Joshua M Thorpe; Courtney H Van Houtven; Betsy L Sleath; Carolyn T Thorpe
Journal:  J Rural Health       Date:  2010       Impact factor: 4.333

4.  Brain microRNAs associated with late-life depressive symptoms are also associated with cognitive trajectory and dementia.

Authors:  Thomas S Wingo; Jingjing Yang; Wen Fan; Se Min Canon; Ekaterina Sergeevna Gerasimov; Adriana Lori; Benjamin Logsdon; Bing Yao; Nicholas T Seyfried; James J Lah; Allan I Levey; Patricia A Boyle; Julia A Schneider; Philip L De Jager; David A Bennett; Aliza P Wingo
Journal:  NPJ Genom Med       Date:  2020-02-06       Impact factor: 8.617

5.  Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease.

Authors:  Cynthia A Munro; Crystal Flynn Longmire; Lea T Drye; Barbara K Martin; Constantine E Frangakis; Curtis L Meinert; Jacobo E Mintzer; Anton P Porsteinsson; Peter V Rabins; Paul B Rosenberg; Lon S Schneider; Daniel Weintraub; Constantine G Lyketsos
Journal:  Am J Geriatr Psychiatry       Date:  2012-12       Impact factor: 4.105

6.  Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis.

Authors:  Raymond L Ownby; Elizabeth Crocco; Amarilis Acevedo; Vineeth John; David Loewenstein
Journal:  Arch Gen Psychiatry       Date:  2006-05

Review 7.  Shared cognitive and behavioral impairments in epilepsy and Alzheimer's disease and potential underlying mechanisms.

Authors:  Jeannie Chin; Helen E Scharfman
Journal:  Epilepsy Behav       Date:  2013-01-13       Impact factor: 2.937

Review 8.  Genomic variants, genes, and pathways of Alzheimer's disease: An overview.

Authors:  Adam C Naj; Gerard D Schellenberg
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2017-01       Impact factor: 3.568

9.  Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease.

Authors:  Marwa Aboukhatwa; Laura Dosanjh; Yuan Luo
Journal:  Mol Neurodegener       Date:  2010-03-12       Impact factor: 14.195

10.  Prevention of depression and sleep disturbances in elderly with memory-problems by activation of the biological clock with light--a randomized clinical trial.

Authors:  Els I S Most; Philip Scheltens; Eus J W Van Someren
Journal:  Trials       Date:  2010-02-23       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.